AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2025
Apr 24, 2025
33148_dirs_2025-04-24_050639d9-a1df-4bf2-bd5b-9bbed272e26c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2025-03-05
Reporting Person: Dolsten Mikael (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-05 | Common Stock | J | 14220 | — | Acquired | 14220 | Direct |
Footnotes
F1: Represent restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will become fully vested on December 31, 2025.
F2: Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, effective March 3, 2025, for services related to the Company's research and development activities. As part of the compensation for services rendered, the Reporting Person received $125,000 of RSUs valued based on the closing price of the Company's common stock on March 3, 2025, which will cliff vest on December 31, 2025.